Wells Fargo Upgrades RxSight to Overweight, Announces $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen has upgraded RxSight (NASDAQ:RXST) from Equal-Weight to Overweight and set a price target of $42.

December 13, 2023 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RxSight's stock rating has been upgraded by Wells Fargo from Equal-Weight to Overweight with a new price target of $42.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest a bullish outlook on the company's performance and potential. The new price target of $42 indicates a significant upside from the current trading price, which can attract investor interest and potentially drive up the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100